Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401002 | 1.00 | OPRK1 (0.46) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL4397929 | 0.91 | POLB (0.40) | OPRK1POLBEPHX2MAPTALDH1A1 | |
| SCHEMBL13643851 | 0.89 | OPRK1 (0.49) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL4397934 | 0.88 | OPRK1 (0.45) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13880959 | 0.88 | POLB (0.46) | POLBMAPTTSHRALDH1A1MEN1 | |
| SCHEMBL4400850 | 0.88 | POLB (0.49) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13643840 | 0.87 | OPRK1 (0.52) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13643871 | 0.87 | OPRK1 (0.52) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL13643847 | 0.87 | OPRK1 (0.45) | OPRK1CA12CA1CA2CA4 | |
| SCHEMBL18249449 | 0.86 | POLB (0.49) | OPRK1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118119386-A | Functionalized carboxylic acids and their use for treating diseases | 埃斯佩尔维塔治疗股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| EP-4281058-A2 | FUNCTIONALIZED LONG-CHAIN CARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230364189-A1 | Method to Improve Neurologic Outcomes in Temperature Managed Patients | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-11-16 | — | — | US | claimed |
| CN-114469937-B | Application of PF-05231023 in preparation of anti-coronavirus infection medicines | 山东大学 | 2023-06-23 | — | — | CN | claimed |
| US-11638745-B2 | Method to improve neurologic outcomes in temperature managed patients | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education (US) | 2023-05-02 | — | — | US | claimed |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| US-20230111520-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| US-20230088633-A1 | FGF21 COMPOSITIONS FOR TREATMENT OR PREVENTION OF NEOVASCULARIZATION OF THE EYE AND METHODS THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | claimed |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-20220288054-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | ANKURA TRUST COMPANY, LLC | 2022-09-15 | — | — | US | claimed |
| CN-115052970-A | Use of fibroblast growth factor activator in culture medium | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2022-09-13 | — | — | CN | claimed |
| WO-2022159808-A2 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159811-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| EP-4003314-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| CN-114469937-A | Application of PF-05231023 in preparation of anti-coronavirus infection medicine | 山东大学 | 2022-05-13 | — | — | CN | claimed |
| US-20260139021-A1 | VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR (FGF21) CODING SEQUENCE | UNIV AUTòNOMA DE BARCELONA (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12629429-B2 | Fibroblast growth factor 21 (FGF21) gene therapy | UNIVERSITAT AUTÓNOMA DE BARCELONA (ES) | 2026-05-19 | — | — | US | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008081418-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288054-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | SLC10A1, FABP1, LIPC | OPRK1 3711/4885CA12 1687/4885CA1 3440/4885 |
| US-12629429-B2 | Fibroblast growth factor 21 (FGF21) gene therapy | FGF1, FGF23, FGF2 | OPRK1 4386/4885CA12 1701/4885CA1 2166/4885 |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | OPRK1 1293/4885CA12 616/4885CA1 1162/4885 |
| US-20260139021-A1 | VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR (FGF21) CODING SEQUENCE | FGF23, FGF1, FGF2 | OPRK1 4432/4885CA12 4542/4885CA1 4841/4885 |
| US-20230088633-A1 | FGF21 COMPOSITIONS FOR TREATMENT OR PREVENTION OF NEOVASCULARIZATION OF THE EYE AND METHODS THEREFOR | VEGFA, FGF1, FGF2 | OPRK1 4786/4885CA12 1840/4885CA1 4034/4885 |
| US-20230111520-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | OPRK1 1608/4885CA12 1552/4885CA1 2051/4885 |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | OPRK1 1995/4885CA12 2579/4885CA1 3048/4885 |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | OPRK1 1555/4885CA12 1659/4885CA1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.